Sofosbuvir

Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM[1].

Product Specifications

CAS Number

[1190307-88-0]

Product Name Alternative

GS-7977; PSI-7977

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/PSI-7977.html

Purity

99.99

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic; warming; heat to 50°C)

Smiles

C[C@@]1(F)[C@H](O)[C@@H](CO[P@](OC2=CC=CC=C2)(N[C@@H](C)C(OC(C)C)=O)=O)O[C@H]1N(C=CC(N3)=O)C3=O

Molecular Formula

C22H29FN3O9P

Molecular Weight

529.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285 (45) :34337-47.|[2]Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56 (6) :3359-68.|[3]Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53 (19) :7202-18.|[4]Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065.